Floatz logo

Iodixanol

Lung Neoplasms

National Cancer Institute (NCI)Small moleculePhase 1/2Dormant
CC
46/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
73/ 100

Competitive context

48 Active assets in the Lung Neoplasms cohort.

Asset / SponsorPhaseRating
Carboplatin
Nanfang Hospital, Southern Medical University
Phase 4BB
Icotinib
Fuda Cancer Hospital, Guangzhou
Phase 4BB
Cyclophosphamide
Pfizer
Phase 3BB
CIS-DIAMMINEDICHLOROPLATINUM II
Nanfang Hospital, Southern Medical University
Phase 3B
Osimertinib
Jin Ying
Phase 2B

View all 50 →

Same molecule, other indications

Iodixanol is also rated in:

carotid stenosisDormant
B
Indicative ·
63 / 100
View asset →
atherosclerosisDormant
B
Indicative ·
62 / 100
View asset →
Colon CancerDormant
B
Indicative ·
59 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →